Antipsychotic-induced hyperprolactinaemia

References

• Kars M, Souverein PC, Herings RM . Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 2009; 94:2729–2734.
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91:4769–4775.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80:1050–1057.
   PubMed Web of Science ®Google Scholar
• Melmed S, Kleinberg D. Anterior pituitary. Larsen P, Kronenberg H, Melmed S, Polonsky K. Williams textbook of endocrinology, 10th. Philadelphia: Saunders, 2003:177–279.
   Google Scholar
• Leblanc H, Lachelin GC, Abu-Fadil S, Yen SS. Effects of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab 1976; 43:668–674.
   PubMed Web of Science ®Google Scholar
• Jacobs LS, Snyder PJ, Wilber JF, Utiger RD, Daughaday WH. Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab 1971; 33:996–998.
   PubMed Web of Science ®Google Scholar
• Kato Y, Shimatsu A, Matsushita N, Ohta H, Imura H. Role of vasoactive intestinal polypeptide (VIP) in regulating the pituitary function in man. Peptides 1984; 5:389–394.
   PubMed Web of Science ®Google Scholar
• Hinuma S, Habata Y, Fujii R . A prolactin-releasing peptide in the brain. Nature 1998; 393:272–276.
   PubMed Web of Science ®Google Scholar
• Thomas GB, Cummins JT, Cavanagh L, Clarke IJ. Transient increase in prolactin secretion following hypothalamo-pituitary disconnection in ewes during anoestrus and the breeding season. J Endocrinol 1986; 111:425–431.
   PubMed Web of Science ®Google Scholar
• Karavitaki N, Thanabalasingham G, Shore HC . Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006; 65:524–529.
   PubMed Web of Science ®Google Scholar
• Arafah BM, Nekl KE, Gold RS, Selman WR. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 1995; 80: 3507–3512.
   PubMed Web of Science ®Google Scholar
• Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am 1988; 17:213–223.
   PubMed Web of Science ®Google Scholar
• Vallette-Kasic S, Morange-Ramos I, Selim A . Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002; 87:581–588.
   PubMed Web of Science ®Google Scholar
• Leslie H, Courtney CH, Bell PM . Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001; 86:2743–2746.
   PubMed Web of Science ®Google Scholar
• Walsh JP, Pullan PT. Hyperprolactinaemia in males: a heterogeneous disorder. Aust N Z J Med 1997; 27:385–390.
   PubMedGoogle Scholar
• Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000; 85:3053–3057.
   PubMed Web of Science ®Google Scholar
• Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980; 303:1511–1514.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986; 104:777–782.
   PubMed Web of Science ®Google Scholar
• Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986; 315: 542–546.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989; 110:526–531.
   PubMed Web of Science ®Google Scholar
• Howlett TA, Wass JA, Grossman A . Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol (Oxf) 1989; 30: 131–140.
   PubMed Web of Science ®Google Scholar
• Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol 2006; 25:395–404.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 2010; 13:195–198.
   PubMed Web of Science ®Google Scholar
• Nicol M, Willis C, Yiangou C, Sinnett D, Shousha S. Relationship between serum prolactin levels and histology of benign and malignant breast lesions: a detailed study of 153 consecutive cases. Breast J 2002; 8:281–285.
   PubMedGoogle Scholar
• Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr Res 2009; 114:6–16.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28S2:55–68.
   PubMed Web of Science ®Google Scholar
• Montgomery J, Winterbottom E, Jessani M . Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004; 65: 1491–1498.
   PubMed Web of Science ®Google Scholar
• Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007; 21:768–773.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Sajjad R, Benjamin F. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 1998; 91:693–695.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Fang VS. Serum prolactin levels in schizophrenia – effect of antipsychotic drugs: a preliminary report. Sachar EJ. Hormones, behavior and psychopathology. New York: Raven, 1976:177–190.
   Google Scholar
• Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005; 66:761–767.
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Cooper TB . Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004; 65:57–61.
   PubMed Web of Science ®Google Scholar
• Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22:46–55.
   PubMedGoogle Scholar
• Potkin SG, Saha AR, Kujawa MJ . Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681–690.
   PubMed Web of Science ®Google Scholar
• Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007; 68:213–223.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64:2291–314.
   PubMed Web of Science ®Google Scholar
• Smith SM. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 2008; 22:63–69.
   PubMedGoogle Scholar
• Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995; 56:137–141.
   PubMed Web of Science ®Google Scholar
• Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002; 181:49–55.
   PubMed Web of Science ®Google Scholar
• Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 2007; 68:361–367.
   PubMed Web of Science ®Google Scholar
• Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 2006; 32:315–326.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006; 31:577–588.
   PubMed Web of Science ®Google Scholar
• Spollen JJ III, Wooten RG, Cargile C, Bartztokis G. Prolactin levels and erectile function in patients treated with risperidone. J Clin Psychopharmacol 2004; 24:161–166.
   PubMed Web of Science ®Google Scholar
• Westheide J, Cvetanovska G, Albrecht C . Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med 2008; 5:2816–2826.
   PubMed Web of Science ®Google Scholar
• Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65:1607–18; quiz 1590, 1760–1761.
   PubMed Web of Science ®Google Scholar
• O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008; 22:70–75.
   PubMedGoogle Scholar
• Lips P, Bouillon R, van Schoor NM . Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) 2010; 73: 277–285.
   PubMed Web of Science ®Google Scholar
• Jung DU, Conley RR, Kelly DL . Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 2006; 67:1391–1396.
   PubMed Web of Science ®Google Scholar
• Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184:503–508.
   PubMed Web of Science ®Google Scholar
• Howes OD, Wheeler MJ, Meaney AM . Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol 2005; 25:259–261.
   PubMed Web of Science ®Google Scholar
• O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005; 25:26–31.
   PubMed Web of Science ®Google Scholar
• Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007; 93:136–143.
   PubMed Web of Science ®Google Scholar
• Melkersson K, Hulting AL. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder. Eur Arch Psychiatry Clin Neurosci 2000; 250:6–10.
   PubMed Web of Science ®Google Scholar
• Pal JK, Sarino WA. Effect of risperidone on prolactinoma growth in a psychotic woman. Psychosom Med 2000; 62:736–738.
   PubMed Web of Science ®Google Scholar
• Konopelska S, Quinkler M, Strasburger CJ, Ventz M. Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia – a case report with a review of the literature. J Clin Psychopharmacol 2008; 28:120–122.
   PubMed Web of Science ®Google Scholar
• Akkaya C, Kaya B, Kotan Z, Sarandol A, Ersoy C, Kirli S. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. J Psychopharmacol 2009; 23:723–726.
   PubMed Web of Science ®Google Scholar
• Szarfman A, Tonning JM, Levine JG, Doraiswamy PM. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26:748–758.
   PubMed Web of Science ®Google Scholar
• Doraiswamy PM, Schott G, Star K, Edwards R, Mueller-Oerlinghausen B. Atypical antipsychotics and pituitary neoplasms in the WHO database. Psychopharmacol Bull 2007; 40:74–76.
   PubMedGoogle Scholar
• Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817–820.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR . Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273–288.
   PubMed Web of Science ®Google Scholar
• Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006; 67:1093–1103.
   PubMed Web of Science ®Google Scholar
• Costa AM, de Lima MS, Faria M, Filho SR, de Oliveira IR, de Jesus Mari J. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol 2007; 21:165–170.
   PubMed Web of Science ®Google Scholar
• Kim KS, Pae CU, Chae JH . Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63:408–413.
   PubMed Web of Science ®Google Scholar
• Keller R, Mongini F. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 2002; 23:233–235.
   PubMed Web of Science ®Google Scholar
• Hoffer ZS, Roth RL, Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009; 50:317–324.
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU, Goff DC . A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009; 70:1348–1357.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010; 30:596–599.
   PubMed Web of Science ®Google Scholar
• Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1495–1499.
   PubMed Web of Science ®Google Scholar
• Miller KK. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectr 2004; 9:28–32.
   PubMed Web of Science ®Google Scholar
• Warren MP, Chua A. Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women's Health Initiative. Growth Horm IGF Res 2006; 16:S98–102.
   Web of Science ®Google Scholar
• Kulkarni J, Riedel A, de Castella AR . Estrogen – a potential treatment for schizophrenia. Schizophr Res 2001; 48: 137–144.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, de Castella A, Fitzgerald PB . Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65:955–960.
   PubMed Web of Science ®Google Scholar
• Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol 2007; 14:488–493.
   PubMed Web of Science ®Google Scholar
• Minnemann T, Schubert M, Freude S . Comparison of a new long-acting testosterone undecanoate formulation versus testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 2008; 31:718–723.
   PubMed Web of Science ®Google Scholar
• Frye PE, Pariser SF, Kim MH, O'Shaughnessy RW. Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 1982; 43:252–253.
   PubMed Web of Science ®Google Scholar
• Cohn JB, Brust J, DiSerio F, Singer J. Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology 1985; 13:173–179.
   PubMed Web of Science ®Google Scholar
• Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 1992; 37:737–740.
   PubMed Web of Science ®Google Scholar
• Bliesener N, Yokusoglu H, Quednow BB, Klingmuller D, Kuhn KU. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. Pharmacopsychiatry 2004; 37:189–191.
   PubMed Web of Science ®Google Scholar
• Miller DE, Sebastian CS. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. J Clin Psychiatry 2005; 66:269–270.
   PubMed Web of Science ®Google Scholar
• Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001; 11:435–440.
   PubMed Web of Science ®Google Scholar
• Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65:187–190.
   PubMed Web of Science ®Google Scholar
• Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000; 23:765–770.
   PubMed Web of Science ®Google Scholar
• Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. BMJ (Clin Res Ed) 1984; 289:1101–1103.
   PubMed Web of Science ®Google Scholar
• Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008; 30:378–380.
   PubMed Web of Science ®Google Scholar